· Published by Health Canada · Official notice
This is duplicated text of a letter from ratiopharm inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 11, 2007
Subject: URGENT - Voluntary Type 1 Recall of ratio-Valproic (valproic acid) 500-mg Enteric-Coated Capsules in Canada
Dear Health Care Professional,
ratiopharm inc. is advising health care professionals of the immediate voluntary recall of all lots of ratio-Valproic (valproic acid) 500-mg enteric-coated capsules (DIN 02140055) due to stability test failures: routine stability testing has indicated that the product's shelf life is not as long as marked on the packaging. As a result, a lesser amount of active ingredient may be released. This may result in inadequate seizure control, potentially putting patients at risk for a greater number of seizures.
ratio-Valproic (valproic acid) is indicated as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. It may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures.
Prescribers:
Pharmacists:
Patients currently taking ratio-Valproic (valproic acid) 500-mg enteric-coated capsules should immediately contact their doctor or pharmacist to identify and determine other treatment options.
No other ratio-Valproic formulation or ratiopharm product is affected by this action.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving ratio-Valproic (valproic acid) 500-mg enteric-coated capsules should be reported to ratiopharm or Health Canada at the following addresses:
ratiopharm inc.
17800, Lapointe
Mirabel QC J7J 1P3
Tel : 1-800-667-6030
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-57-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866-234-2345
Fax: 866-678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate - Drug Compliance Verification & Investigation Unit (DCVIU)
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 613-941-3967
Fax: 613-952-9805
ratiopharm reiterates its commitment to the health and safety of patients and the delivery of quality products.
Should you have any questions or require additional information regarding the recall of ratio-Valproic (valproic acid) 500-mg enteric-coated capsules, please contact ratiopharm at 1-800-667-6030
Sincerely,
original signed by
Martha Kahne-Mercure
Vice-President Quality
ratiopharm